These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 7703832)
21. Retaliation against tumor cells showing aberrant HLA expression using lymphokine activated killer-derived T cells. Falk CS; Noessner E; Weiss EH; Schendel DJ Cancer Res; 2002 Jan; 62(2):480-7. PubMed ID: 11809699 [TBL] [Abstract][Full Text] [Related]
22. Natural killer cell-mediated inhibition of growth of myeloid and lymphoid clonogenic leukemias. Savary CA; Lotzová E Exp Hematol; 1989 Feb; 17(2):183-7. PubMed ID: 2912742 [TBL] [Abstract][Full Text] [Related]
23. T cells and monocytes regulate the generation and functional activity of natural killer-derived lymphokine-activated killer cells. Atzpodien J; Gulati SC Stem Cells; 1993 Nov; 11(6):511-8. PubMed ID: 8111310 [TBL] [Abstract][Full Text] [Related]
24. On the relative roles of interleukin-2 and interleukin-10 in the generation of lymphokine-activated killer cell activity. Spagnoli GC; Juretic A; Schultz-Thater E; Dellabona P; Filgueira L; Hörig H; Zuber M; Garotta G; Heberer M Cell Immunol; 1993 Feb; 146(2):391-405. PubMed ID: 8174177 [TBL] [Abstract][Full Text] [Related]
25. [Preparation of NK-enriched LAK cells--their potential cytotoxic and ADCC activities]. Kobayashi Y; Sudo T; Matsushita N; Nakao M; Tanaka Y; Shimizu K; Tanigawa K; Aruga A Gan To Kagaku Ryoho; 2003 Oct; 30(11):1776-9. PubMed ID: 14619517 [TBL] [Abstract][Full Text] [Related]
26. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines. Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754 [TBL] [Abstract][Full Text] [Related]
27. Interplay in vitro between ACTH, beta-endorphin, and glucocorticoids in the modulation of spontaneous and lymphokine-inducible human natural killer (NK) cell activity. Gatti G; Masera RG; Pallavicini L; Sartori ML; Staurenghi A; Orlandi F; Angeli A Brain Behav Immun; 1993 Mar; 7(1):16-28. PubMed ID: 8386029 [TBL] [Abstract][Full Text] [Related]
28. Thrombin modulation of natural killer activity in human peripheral lymphocytes. Naldini A; Carney DH Cell Immunol; 1996 Aug; 172(1):35-42. PubMed ID: 8806804 [TBL] [Abstract][Full Text] [Related]
29. Adherent lymphokine-activated killer cells in chronic myelogenous leukemia: a benign cell population with potent cytotoxic activity. Verfaillie C; Miller W; Kay N; McGlave P Blood; 1989 Aug; 74(2):793-7. PubMed ID: 2473805 [TBL] [Abstract][Full Text] [Related]
30. Relative roles of natural killer- and T cell-mediated anti-leukemia effects in chronic myelogenous leukemia patients treated with interferon-alpha. Pawelec G; Da Silva P; Max H; Kalbacher H; Schmidt H; Bruserud O; Zügel U; Baier W; Rehbein A; Pohla H Leuk Lymphoma; 1995 Aug; 18(5-6):471-8. PubMed ID: 8528055 [TBL] [Abstract][Full Text] [Related]
32. Serum and acute phase protein modulation of the effector phase of lymphokine-activated killer cells. Clayman GL; Taylor DL; Liu FJ; Lavedan P; Savage HE; Schantz SP Laryngoscope; 1993 Mar; 103(3):299-307. PubMed ID: 7680086 [TBL] [Abstract][Full Text] [Related]
34. Modulation of natural killing activity by lymphoblastoid interferon in cancer patients. Koren HS; Brandt CP; Tso CY; Laszlo J J Biol Response Mod; 1983; 2(2):151-65. PubMed ID: 6644332 [TBL] [Abstract][Full Text] [Related]
35. Modulation of natural killer and antibody-dependent cellular cytotoxicity by interferon and interleukin-2 in chronic myeloid leukemia patients in remission. Dabholkar M; Tatake R; Amin K; Advani S; Gangal S Oncology; 1989; 46(2):123-7. PubMed ID: 2785254 [TBL] [Abstract][Full Text] [Related]
36. Diminished A-LAK cytotoxicity and proliferation accompany disease progression in chronic myelogenous leukemia. Verfaillie C; Kay N; Miller W; McGlave P Blood; 1990 Jul; 76(2):401-8. PubMed ID: 1695114 [TBL] [Abstract][Full Text] [Related]
37. Studies on natural killer cells in chronic myeloid leukemia patients in remission. Dabholkar M; Tatake RJ; Advani S; Gangal SG Neoplasma; 1990; 37(1):47-53. PubMed ID: 1690865 [TBL] [Abstract][Full Text] [Related]
39. Evaluation of NK and LAK cell activities in neoplastic patients during treatment with morphine. Provinciali M; Di Stefano G; Raffaeli W; Pari G; Desiderio F; Fabris N Int J Neurosci; 1991 Jul; 59(1-3):127-33. PubMed ID: 1774133 [TBL] [Abstract][Full Text] [Related]
40. Effects of in vitro treatment with fluticasone propionate on natural killer and lymphokine-induced killer activity in asthmatic and healthy individuals. Di Lorenzo G; Esposito Pellitteri M; Drago A; Di Blasi P; Candore G; Balistreri C; Listi F; Caruso C Allergy; 2001 Apr; 56(4):323-7. PubMed ID: 11284800 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]